Recent News

Cohort Study of CLL and Leukemia Cutis From the French Innovative Leukemia Organization

Retrospective Look at Therapeutic Considerations for Adolescent and Young Adults With CLL

Multi-hit TP53-Aberrant CLL: Focus on Prognostication and Management

Can Baseline Geriatric Domains Help to Identify High-Risk Patients With CLL?

Novel BCL2 Inhibitor Under Study in Resistant CLL and Other Blood Cancers

Antibody Response to COVID-19 Vaccine in Patients With CLL

EHA2021: CLL14 Follow-up Supports Use of Venetoclax Plus Obinutuzumab

ASCO 2021: Converting Peripheral Blood Mononuclear Cells Into Autologous Cellular Therapy for CLL

What Next? Update on Management of Resistant CLL After First-Line Therapy

EHA2021: CLL14 Follow-up Supports Use of Venetoclax Plus Obinutuzumab

ASCO 2021: 4-Year Update of ELEVATE-TN Trial of Acalabrutinib Regimens in CLL

EHA2021: ALPINE Trial of Zanubrutinib Versus Ibrutinib in Resistant CLL

EHA2021: Phase III GLOW Trial of Ibrutinib and Venetoclax as First-Line CLL Therapy

ASCO 2021: Fixed-Duration Treatment With Ibrutinib Plus Venetoclax in CLL

ASCO 2021: Phase III Noninferiority Trial of Acalabrutinib Versus Ibrutinib in CLL

Richter’s Transformation in CLL: B-Cell Receptor Signals and Genetic Lesions

Impact of Ibrutinib on T-Cell Responses in CLL

Rare Case of Metastatic CLL Presenting as Focal Mass in the Gallbladder

Deletion 17p Subclones and Outcomes in Patients With CLL

FDA Brief: New Drug Application Accepted for CD20-Targeted CAR T-Cell Therapy for CLL

Genetic Relationship Between CLL and Non-Melanoma Skin Cancer?

Does Ibrutinib Therapy Induce Host Antitumor Immune Activation in CLL?

Potential Biomarkers in CLL Harboring Trisomy 12 Under Study

Case Study: Rare Richter Transformation of CLL Involving the Ear

Untangling Neutrophil Clues to Increased Bacterial Infections in CLL

Serum APRIL Levels: Novel Prognostic Marker Under Study in CLL

Rare Case of Acute Macular Neuroretinopathy in a Woman With CLL

AACR 2021: T-Cell Infusion Product Under Investigation in Resistant CLL

Concurrent Adenoid Cystic Carcinoma and CLL: Case Report

Response to Induction Therapy and Ofatumumab Consolidation in Patients With CLL

Identifying Prognostic Markers for Early-Stage CLL

Novel Agent Under Study in CLL: Dual Inhibitory Activity Reported

High-Risk CLL: GENUINE Trial of Ublituximab Plus Ibrutinib Versus Ibrutinib Alone

BTK Inhibitor and Cerebral Invasive Aspergillosis: Case Report in CLL

Toxicity and Treatment Discontinuation in CLL: U.S. Veterans Health Administration Study

Successful Addition of a New Treatment Arm to the Phase III FLAIR Trial in CLL

Subclinical Coagulopathy Associated With Obinutuzumab Infusion for CLL?

Preclinical Study of Combination Therapy for CLL: Avadomide Plus Checkpoint Inhibition

Case Report in CLL: Is Sclerouveitis an Off-Target Effect of Ibrutinib Treatment?

Blood Clots: New Adverse Event With First Infusion of Obinutuzumab for CLL?

Case Study: Personalized Low-Dose Immunotherapy for Poor-Prognosis CLL

Ibrutinib Versus Idelalisib Plus Rituximab in Resistant CLL

Blood Eosinophil Count and Prognosis in CLL

TCT 2021: Case of Accelerated-Phase CLL/SLL Relapsing as PTCL After Transplantation

TCT 2021: Update on Transplant Outcomes for CLL in Australasia

Case Report: CLL With Right Temporal Lobe Tumor